Christian F. Meyer
Johns Hopkins University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christian F. Meyer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:58 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06263231 · A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)Intensity Therapeutics, Inc. · recruiting · Sarcoma,Soft Tissue · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:58 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- 83 citationsRCR 10.0
- A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma.Int J Cancer · 201336 citationsRCR 1.1
- 20 citationsRCR 1.2
- Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer.Cancer Res Commun · 202311 citationsRCR 1.8
- Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.J Clin Oncol · 202411 citationsRCR 1.2
- Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study.EBioMedicine · 20253 citationsRCR 0.6